An update on North American randomized studies in non-small cell lung cancer

Jr Bunn P.A., E. E. Vokes, C. J. Langer, J. H. Schiller

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Lung cancer is the leading cause of cancer-related death in North America and Europe. Approximately 75% of lung cancer is non-small cell lung cancer, and approximately 70% of these patients present with unresectable disease. In the past, these patients were treated with either palliative radiotherapy or other best supportive care measures. The survival of patients with stage IV disease was extremely poor. Median survival was between 16 and 17 weeks, and only 10% to 15% of patients were alive at 1 year. Cisplatin- based chemotherapy was the first therapy to show that survival could be improved. Randomized trials that compared best supportive care, including palliative radiotherapy, with cisplatin-based combination therapy showed modest improvement in the survival of these patients. On average, the median survival of patients improved by 10 weeks (from 16 to 26 weeks) and the 1- year survival rate improved by 10% (from 15% to 25%). These cisplatin-based therapies also relieved symptoms and improved quality of life at acceptable costs, which were sometimes less than those associated with best supportive care. More recently, a number of new chemotherapeutic agents (gemcitabine, paclitaxel, docetaxel, vinorelbine, and irinotecan) with high, single-agent activities and novel mechanisms of action have shown superior activity and improved quality of life when used in combination with conventional agents and with each other.

Original languageEnglish (US)
Pages (from-to)2-10
Number of pages9
JournalSeminars in Oncology
Volume25
Issue number4 SUPPL.
StatePublished - 1998

Fingerprint

Non-Small Cell Lung Carcinoma
Survival
Cisplatin
irinotecan
docetaxel
gemcitabine
Lung Neoplasms
Radiotherapy
Quality of Life
North America
Paclitaxel
Palliative Care
Therapeutics
Survival Rate
Costs and Cost Analysis
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Bunn P.A., J., Vokes, E. E., Langer, C. J., & Schiller, J. H. (1998). An update on North American randomized studies in non-small cell lung cancer. Seminars in Oncology, 25(4 SUPPL.), 2-10.

An update on North American randomized studies in non-small cell lung cancer. / Bunn P.A., Jr; Vokes, E. E.; Langer, C. J.; Schiller, J. H.

In: Seminars in Oncology, Vol. 25, No. 4 SUPPL., 1998, p. 2-10.

Research output: Contribution to journalArticle

Bunn P.A., J, Vokes, EE, Langer, CJ & Schiller, JH 1998, 'An update on North American randomized studies in non-small cell lung cancer', Seminars in Oncology, vol. 25, no. 4 SUPPL., pp. 2-10.
Bunn P.A. J, Vokes EE, Langer CJ, Schiller JH. An update on North American randomized studies in non-small cell lung cancer. Seminars in Oncology. 1998;25(4 SUPPL.):2-10.
Bunn P.A., Jr ; Vokes, E. E. ; Langer, C. J. ; Schiller, J. H. / An update on North American randomized studies in non-small cell lung cancer. In: Seminars in Oncology. 1998 ; Vol. 25, No. 4 SUPPL. pp. 2-10.
@article{4812927366fe4ba7817bedb09f5da298,
title = "An update on North American randomized studies in non-small cell lung cancer",
abstract = "Lung cancer is the leading cause of cancer-related death in North America and Europe. Approximately 75{\%} of lung cancer is non-small cell lung cancer, and approximately 70{\%} of these patients present with unresectable disease. In the past, these patients were treated with either palliative radiotherapy or other best supportive care measures. The survival of patients with stage IV disease was extremely poor. Median survival was between 16 and 17 weeks, and only 10{\%} to 15{\%} of patients were alive at 1 year. Cisplatin- based chemotherapy was the first therapy to show that survival could be improved. Randomized trials that compared best supportive care, including palliative radiotherapy, with cisplatin-based combination therapy showed modest improvement in the survival of these patients. On average, the median survival of patients improved by 10 weeks (from 16 to 26 weeks) and the 1- year survival rate improved by 10{\%} (from 15{\%} to 25{\%}). These cisplatin-based therapies also relieved symptoms and improved quality of life at acceptable costs, which were sometimes less than those associated with best supportive care. More recently, a number of new chemotherapeutic agents (gemcitabine, paclitaxel, docetaxel, vinorelbine, and irinotecan) with high, single-agent activities and novel mechanisms of action have shown superior activity and improved quality of life when used in combination with conventional agents and with each other.",
author = "{Bunn P.A.}, Jr and Vokes, {E. E.} and Langer, {C. J.} and Schiller, {J. H.}",
year = "1998",
language = "English (US)",
volume = "25",
pages = "2--10",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL.",

}

TY - JOUR

T1 - An update on North American randomized studies in non-small cell lung cancer

AU - Bunn P.A., Jr

AU - Vokes, E. E.

AU - Langer, C. J.

AU - Schiller, J. H.

PY - 1998

Y1 - 1998

N2 - Lung cancer is the leading cause of cancer-related death in North America and Europe. Approximately 75% of lung cancer is non-small cell lung cancer, and approximately 70% of these patients present with unresectable disease. In the past, these patients were treated with either palliative radiotherapy or other best supportive care measures. The survival of patients with stage IV disease was extremely poor. Median survival was between 16 and 17 weeks, and only 10% to 15% of patients were alive at 1 year. Cisplatin- based chemotherapy was the first therapy to show that survival could be improved. Randomized trials that compared best supportive care, including palliative radiotherapy, with cisplatin-based combination therapy showed modest improvement in the survival of these patients. On average, the median survival of patients improved by 10 weeks (from 16 to 26 weeks) and the 1- year survival rate improved by 10% (from 15% to 25%). These cisplatin-based therapies also relieved symptoms and improved quality of life at acceptable costs, which were sometimes less than those associated with best supportive care. More recently, a number of new chemotherapeutic agents (gemcitabine, paclitaxel, docetaxel, vinorelbine, and irinotecan) with high, single-agent activities and novel mechanisms of action have shown superior activity and improved quality of life when used in combination with conventional agents and with each other.

AB - Lung cancer is the leading cause of cancer-related death in North America and Europe. Approximately 75% of lung cancer is non-small cell lung cancer, and approximately 70% of these patients present with unresectable disease. In the past, these patients were treated with either palliative radiotherapy or other best supportive care measures. The survival of patients with stage IV disease was extremely poor. Median survival was between 16 and 17 weeks, and only 10% to 15% of patients were alive at 1 year. Cisplatin- based chemotherapy was the first therapy to show that survival could be improved. Randomized trials that compared best supportive care, including palliative radiotherapy, with cisplatin-based combination therapy showed modest improvement in the survival of these patients. On average, the median survival of patients improved by 10 weeks (from 16 to 26 weeks) and the 1- year survival rate improved by 10% (from 15% to 25%). These cisplatin-based therapies also relieved symptoms and improved quality of life at acceptable costs, which were sometimes less than those associated with best supportive care. More recently, a number of new chemotherapeutic agents (gemcitabine, paclitaxel, docetaxel, vinorelbine, and irinotecan) with high, single-agent activities and novel mechanisms of action have shown superior activity and improved quality of life when used in combination with conventional agents and with each other.

UR - http://www.scopus.com/inward/record.url?scp=0031949039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031949039&partnerID=8YFLogxK

M3 - Article

C2 - 9728578

AN - SCOPUS:0031949039

VL - 25

SP - 2

EP - 10

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL.

ER -